Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Adv
Main Authors: Pasquini, Marcelo C., Hu, Zhen-Huan, Curran, Kevin, Laetsch, Theodore, Locke, Frederick, Rouce, Rayne, Pulsipher, Michael A., Phillips, Christine L., Keating, Amy, Frigault, Matthew J., Salzberg, Dana, Jaglowski, Samantha, Sasine, Joshua P., Rosenthal, Joseph, Ghosh, Monalisa, Landsburg, Daniel, Margossian, Steven, Martin, Paul L., Kamdar, Manali K., Hematti, Peiman, Nikiforow, Sarah, Turtle, Cameron, Perales, Miguel-Angel, Steinert, Patricia, Horowitz, Mary M., Moskop, Amy, Pacaud, Lida, Yi, Lan, Chawla, Raghav, Bleickardt, Eric, Grupp, Stephan
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2020
נושאים:
Immunobiology and Immunotherapy
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656920/
https://ncbi.nlm.nih.gov/pubmed/33147337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003092
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים